stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.66
0.24
+2.55%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) EV/Sales
Telix Pharmaceuticals Limited has no meaningful EV/Sales: its trailing twelve-month sales is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | n/m |
| TLX Telix Pharmaceuticals Limited | n/m |
| CELC Celcuity, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.2× |
| IDYA IDEAYA Biosciences, Inc. compare | 63.7× |
| VRDN Viridian Therapeutics, Inc. compare | 91.0× |
| DNLI Denali Therapeutics Inc. compare | 143× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)